The anticipated FDA's Pharmacogenomic Guidance Document holds the promise that 2005 will be an extraordinary year for the advancement of the capabilities of microarrays. Microarrays build bridges on which biologists and clinicians can meet to understand, diagnose, and treat diseases. The promises of microarrays are:

rapid access to molecular pathways 
more precise diagnosis and prognosis of diseases 
better understanding of drug action 
better definitions of therapeutic strategies

That, coupled with the FDA's growing interest in the use of microarray-based genomic diagnostic devices, holds a bright future for both researchers developing pharmaceuticals and clinicians performing diagnostics. Optimizing "arrays" depends on carefully assessing your specific purposes. Cambridge Healthech Institute's Microarrays in Medicine: Arrays of Possibilities, will provide practical information and results about new technical developments and specific applications to help determine which arrays are best for your specific application or research need.

Carol Dinerstein
Email: dinerstein@healthtech.com
Phone: 617-630-1371